- Home
- DTST vs BIVI Comparison
DTST vs BIVI Comparison
Compare DTST & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | BIVI |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | DTST | BIVI |
|---|---|---|
| Price | $4.06 | $1.31 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 66.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $0.62 |
| 52 Week High | $5.44 | $9.09 |
Technical Indicators
Market Signals| Indicator | DTST | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 48.28 |
| Support Level | $3.99 | $1.22 |
| Resistance Level | $4.13 | $1.68 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 70.00 | 34.37 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.